SlideShare a Scribd company logo
Advances in Treating
Chronic Pain and Addiction
Presenters:
• Michael Gavin, MBA, President, PRIUM
• Jennifer Saddy, Director of Workers’ Compensation,
American Airlines
• David R. Gastfriend, MD, Scientific Advisor, Treatment
Research Institute
Third-Party Payer Track
Moderator: Michael C. Barnes, JD, Executive Director,
Center for Lawful Access and Abuse Deterrence, and
Member, Rx and Heroin Summit National Advisory Board
Disclosures
• Michael Gavin, MBA; Jennifer Saddy; and
Michael C. Barnes, JD, have disclosed no
relevant, real, or apparent personal or
professional financial relationships with
proprietary entities that produce healthcare
goods and services.
• David R. Gastfriend, MD – Future royalty:
American Society of Addiction Medicine
Disclosures
• All planners/managers hereby state that they or their
spouse/life partner do not have any financial
relationships or relationships to products or devices
with any commercial interest related to the content of
this activity of any amount during the past 12 months.
• The following planners/managers have the following to
disclose:
– John J. Dreyzehner, MD, MPH, FACOEM – Ownership
interest: Starfish Health (spouse)
– Robert DuPont – Employment: Bensinger, DuPont &
Associates-Prescription Drug Research Center
Learning Objectives
1. Outline mental and behavioral issues and their
influence on chronic pain.
2. Identify strategies to address psychosocial pain
issues when managing chronic pain and claims
involving chronic pain.
3. Explain the basis and impacts of the new federal
requirements for state Medicaid directors to
implement the ASAM Criteria.
4. Describe a tool for implementing the new ASAM
Criteria requirement.
THIRD-PARTY PAYER TRACK: ADVANCES
IN TREATING CHRONIC PAIN AND
ADDICTION
Michael Gavin, PRIUM
5
Disclosure Statement
Michael Gavin, President of PRIUM, wishes to disclose that
PRIUM is a wholly owned subsidiary of Ameritox. Michael
will present this content in a fair and balanced manner.
Learning Objectives
1. Outline mental and behavioral issues and their
influence on chronic pain.
2. Identify strategies to address psychosocial pain
issues when managing chronic pain and claims
involving chronic pain.
3. Explain the basis and impacts of the new federal
requirements for state Medicaid directors to
implement the ASAM Criteria.
4. Describe a tool for implementing the new ASAM
Criteria requirement.
Comorbid AMI, SUD, CNCP
“ 9 million persons
in the United States
report long-term
medical use of
opioids.”
- CDC MMWR 2012
Each of the individual populations drives significant healthcare costs; the intersections of the
populations represent particularly complex patients that require innovative and focused management
A. Disease impacts mental health
• 30% of those living with a non-communicable disease
report a concurrent mental disorder.1
B. Mental Health impacts physical health
• Conversely, more than two-thirds of people with a
mental disorder have been shown to have at least one
other chronic NCD. 1
C. Psychosocial and Socioeconomic status modify
both effects
• An individual of lesser social and economic status is
more likely to suffer comorbid mental illness with a
non-communicable disease or disorder. 2
1. (Druss BG, Mental disorders and medical comorbidity.)
2. (Marnett K, Epidemiology of multimorbidity and
implications for health care, research, and medical
education: a cross-sectional study.)
9
Bidirectional Association
Physical health and mental health are intrinsically linked. Psychological factors are reciprocally
interactive in the initiation and expression of the pathology of chronic disease.
• Adverse Childhood Exposures
• The most prevalent of the 7 measured exposures was
substance abuse in the household at (~26%)
• Likelihood of childhood exposure:
• 25% chance to have been exposed to 1 category
• 6% chance to have been exposed to 4 or more categories
• Likelihood of illicit drug use:
• 11% with 1 exposure
• 28% with 4 or more exposures
10
Predicting Substance Abuse
The ACE study followed Kaiser patients from 1995-97. While chronic disease and risky health behaviors
are strongly predicted by ACEs, interventions focused on children are far from implementation.
A. Duration1
• 1-year disability risk is doubled by each of:
– Receiving more than 7 day supply of opioids within the first 6 weeks post injury.
– Receipt of 2 opioid prescriptions in 6 weeks post injury.
– Receipt of >150mg MED in 6 weeks post injury.
B. Mortality2,3
• Nationally, persons with anxiety/depression have a 60% higher mortality and die an
average of 8 years earlier than persons without these illnesses.
• Anxiety/depression attribute to 88,000 deaths each year.
• Prescription painkillers killed more than 16,000 in 2013 or 44 people/day.
C. Expenditures4,5
• Employees treated for depression (most commonly occurring) incurred annual per
capita health and disability costs of $5,415.
• Compared with claims not prescribed opioids, claims prescribed SA opioids are 2.8
times more expensive and claims prescribed LA opioids are 9.3 times more expensive.
1. GM Franklin et al., “early opioid prescription and subsequent disability among workers with back injuries: the Disability Risk Identification
Study Cohort.” Spine 33.2 (2008)
2. Pratt, Laura A., et al., “Excess mortality due to depression and anxiety in the United States.” General Hospital Psychiatry (2015)
3. CDC. National Vital Statistics System mortality data. (2015)
4. Druss, BG et al., “Health and disability costs of depressive illness in a major US corporation.” Am. Journal of Psychiatry 157.8 (2000)
5. White, JA., et al., “Thhe effect of opioid use on workers’ compensation claim cost in the state of Michigan. “J. of Occ and Env. Med (2012)
11
Impact on Claims
Comorbid AMI and CNCP are synergistically disabling and treated as a single disease state using
opiates. Co-occurring AMI and CNCP cause greater disability than each condition taken separately.
Primary Care Problem?
Family practice and internal medicine doctors are responsible for about 28 million opioid claims vs. a
little over 3 million for pain management and interventional pain management combined.
• Stigma contributes to a host of adverse
outcomes for people with SUD:
– Poor mental and physical health.1,2
– Non-completion of treatment for SUD.3
– Delayed recovery and reintegration.4,5
• Stigma also presents a barrier to treatment:
– Causing lowered utilization,6,7
– And differential treatment.8
Influence of Stigma
1. Stigma, discrimination and the health of illicit drug users. Ahern J., Stuber J., Galea S. Article Drug Alcohol Depend, 2007
2. On stigma and its consequences: evidence from a longitudinal study of men with dual diagnoses of mental illness and substance abuse
Link B., Struening E. L., Rahav M., Phelan J. C., Nuttbrock L. Article J Health Soc Behav, 1997
3. Perceptions of discriminatory treatment by staff as predictorsof drug treatment completion: utility of a mixed methods approach
Brener L., von Hippel W., von Hippel C., Resnick I., Treloar C. Article Drug Alcohol Rev, 2010
4. The contextual factors that foster and hinder the process of recoveryfor alcohol dependentwomen
Brewer M. K. Article J Addict Nurs, 2006
5. Nowhere to go: how stigma limits the options of female drug users after release from jail
van Olphen J., Eliason M. J., Freudenberg N., Barnes M. Article Subst Abuse Treat Prev Policy, 2009
6. Utilization of drug treatment programs by methamphetamine users: the role of social stigma
Semple S. J., Grant I., Patterson T. L. Article Am J Addict, 2005
7. Equity of access to treatment, and barriers to treatment for illicit drug use in Australia
Digiusto E., Treloar C. Article Addiction, 2007
8. Are drug treatment services only for ‘thieving junkie scumbags’? Drug users and the management of stigmatised identities
Radcliffe P., Stevens A. Article Soc Sci Med, 2008
Havassy BE, Alvidrez J, Mericle AA. Disparities in Use of Mental Health and
Substance Abuse Services by Persons with Co-occurring
Disorders.Psychiatric services (Washington, DC). 2009;60(2):217-223.
doi:10.1176/appi.ps.60.2.217.
14
Comorbid Treatment Rates
Patients with co-occurring disorders need to navigate two systems of care to obtain treatment. Those
who receive treatment in one sector may not receive adequate treatment in the other sector.
Political Hope?
“…we need a revolution in this country in
terms of mental health treatment.“
- Sen. Bernie Sanders
Democratic Presidential Debate, 1/17/16
"We have to move away from treating the
use of drugs as a crime and instead, move
it to where it belongs, as a health issue.”
- Sec. Hillary Clinton
Democratic Presidential Debate, 1/17/16
"You have the most conservative
Republican governors and the most
liberal Democratic governors agreeing"
on the urgent need to get something
done.
- Gov. Pete Shumliin, VT, NY Times, 2/22/16
“The victims of addiction deserve
treatment...“
- Gov. Chris Christie
ABC News, 1/12/16
“It’s very debilitating when you have a
loved one who’s struggling and you can’t
control it. I don’t know what it’s like to
lose a daughter. But I almost did.”
Gov. Jeb Bush
Huffington Post, 11/5/15
“This is a problem that, for me, I
understand firsthand.”
- Sen. Ted Cruz
Republican Presidential Debate, 2/6/16
• Web: www.prium.com
• Blog: www.priumevidencebased.com
• Twitter: @PRIUM1
• LinkedIn:
https://www.linkedin.com/company/prium-
medical-cost-management
16
Connect with PRIUM
THIRD-PARTY PAYER TRACK: ADVANCES
IN TREATING CHRONIC PAIN AND
ADDICTION
Jennifer Saddy, American Airlines
17
Learning Objectives
1. Outline mental and behavioral issues and their
influence on chronic pain.
2. Identify strategies to address psychosocial pain
issues when managing chronic pain and claims
involving chronic pain.
3. Explain the basis and impacts of the new federal
requirements for state Medicaid directors to
implement the ASAM Criteria.
4. Describe a tool for implementing the new ASAM
Criteria requirement.
• Redesign of the American Airlines Workers’
Compensation (WC) program in 2014 after
merger with US Airways
– Redefined the roles of the WC team
– Program covers over 120,000 employees and 3 wholly
owned subsidiaries.
– At least 15 union groups.
• New program focused on 2 claim tracks:
– New workers’ compensation claims,
– And the legacy on-going existing claims.
American Airlines WC
• Early intervention of the claim process and
additional resources provided for the employee
– Provide more meaningful interaction with the injured
employees
– Employer, Adjuster and Nurse Case Manager
• Direction of care & partner with the treating
physician (to the extent that is allowable per state
law).
• Collaboration and open communication between
all parties in the claims process
New WC Claims
• Early intervention is key to meaningful impact for
the injured employee
– Need to identify early red flags such as unclear
diagnosis and increasing opioid usage
• Provide the additional resources early in the
process to ensure appropriate treatment plan
– Treating physician
– Physician to physician discussions
– Nurse Case Manager
– Utilization Review
Chronic Pain Claims
• 5,874 WC claims open December 2013 some over
20 years old
• Goal was to resolve these claims but chronic pain
and pharmacy usage was a significant challenge
• Significant pharmacy usage in claims 2+ years old
and growing pharmacy trend and ongoing
disability
• Engaged pharmacy experts and physician
resources in attempts to change trajectory of
medical care to allow more function of the
injured employee
Existing WC Claims
• 40% reduction in open Workers Compensation
claims for American Airlines since December
2013
• Reduction in pharmacy costs by 5% (even with
30% more claims with the US Airways merger)
• Reduced disability by an average of 11 days or
25%
Results
Precise Data for Imprecise Behavior:
Why National Standards
Make a Difference
David R. Gastfriend MD
Chief Architect, CONTINUUMTM – The ASAM Criteria Decision Engine
Scientific Advisor – Treatment Research Institute
Disclosure of Relevant Financial Relationships
Name Commercial
Interests
Relevant
Financial
Relationships:
What Was
Received
Relevant
Financial
Relationships:
For What Role
No Relevant
Financial
Relationships
with Any
Commercial
Interests
David Gastfriend Recovery
Search
Alkermes
Kaleo
Indivior
Royalty from
ASAM, Inc.
Stock,Consulting
Consulting
Consulting
Pres. & CEO
Former VP, Sci.
Communications
Adv. Board
Adv. Board
ACA, Parity & Health IT Acts: Huge Implications
The Affordable Care Act (2010)
• Phasing-out fee-for-service
• Penalties now charged for preventable readmissions
• By 2018, 50% of CMS funds will be paid
through alternative payment methods
• Value-based payment, Case-based rates, Pay-for-performance
• Elevates importance of SUD because tens of millions
with higher SUD prevalence become insured
• SUD gets a seat at the table
…but will it be THE HOT SEAT???
ACA, Parity & Health IT Acts: Huge Implications
The Mental Health Parity and Addiction Equity Act (2008):
• Rules & lawsuits – slow in coming, but THEY’RE HERE
• Published medical necessity criteria, e.g., ASAM Criteria
• Equal coverage for SUD as for medical/surgical care
• No “non-quantitative treatment limits”
if not used for med/surg benefits (e.g., prior authorization)
• Kennedy Forum & TRI Online Appeals Guide
• SUD finally gets a seat at the table
www.thekennedyforum.org
www.tresearch.org
ACA, Parity & Health IT Acts: Huge Implications
The Health InfoTech (HITECH) Act (2009): Nowhere to hide
• Incentives for EHR adoption in general healthcare
• SUD behind the curve – competitive pressures now driving
• Data integration on the way…HIPAA & 42CFR – being resolved:
• SAMHSA’s Consent to Share (C2S) web-app is coming:
Patient selects which data can be shared
between which providers & systems
• Not only data storage/retrieval,
but also clinical decision support
and quality/outcomes tracking
…for pay-for-performance
PREVALENCE OF CO-MORBIDITY
(Medicaid; Percent with Chronic Medical +/- Behavioral Disease)
29
Hypertension
Diabetes
Coronary Heart
Disease
Congestive Heart
Failure
Asthma and/or
COPD
31.4%
32.1%
26.3%
30.1%
23.8%
68.6%
67.9%
73.7%
69.9%
76.2%
No Behavioral Health Problem With 1 or More Behavioral Health Problem
29
Boyd, C., Clark, R., Leff, B., Richards, T., Weiss, C., Wolff, J. (2011, August).
Clarifying Multimorbidity for Medicaid Programs to Improve Targeting and Delivering Clinical Services. Presented to SAMHSA, Rockville, MD.
IMPACT OF CO-MORBIDITY ON PER CAPITA COSTS
(Medicaid-Only Beneficaries with Co-Occurring Disorders)
30Boyd, C., Clark, R., Leff, B., Richards, T., Weiss, C., Wolff, J. (2011, August).
Clarifying Multimorbidity for Medicaid Programs to Improve Targeting and Delivering Clinical Services. Presented to SAMHSA, Rockville, MD.
30
Addiction Assessment & Treatment Planning:
• Non-standard, “intuitive”, then “find out the rest later…”
• Managed Care wants more data: Telephone tag (90 min – 3 days)
• Most insurers’ medical necessity criteria are proprietary
• Absent precision & validity, emphasis is on cost, not quality
• 1991: ASAM Patient Placement Criteria…a teaching tool
• States create their own Criteria (CASAM, MASAM, NYSAM…)
• “ASAM” in Major US MCO: ~50% of cases were denials
• on appeal: ~50% reversed; on review ~50% reversed again!
• By 2000s, SAMHSA & CSAT called on ASAM for a standard
Modality Matching:
Many studies, e.g., Project MATCH – but few findings
(Gastfriend & McLellan, Med Clin NA, 1997)
Placement Matching:
Multiple studies; ASAM model – consistent signals
(Gastfriend, Addiction Treatment Matching, Haworth Press, 2004)
Support:
• NIDA: Validation - R01-DA08781 & K24-DA00427
• NIAAA: ASAM Software - SBIR grant R44-AA12004
• CSAT: Access to Recovery Initiative - grant 270-02-7120
• Belgian National Fund for Scientific Research
• Belgian American Educational Foundation
• Central Norway Health Trust /Rusbehandling Midt-Norge
• SAMHSA: Open Behavioral Health IT Architecture Program
Advances in Treatment Matching
ASAM Text: Hundreds of Decision Rules
To place patients in the least intensive & restrictive care
that meets the patient’s multi-dimensional needs
and affords optimal treatment outcome
www.ASAMcriteria.org
www.haworthpress.com
Screening Diagnosis Severity Readiness &
Relapse Potential
Patient Placement Criteria
DIMENSIONS
Intoxication
Withdrawal
Biomedical Emotional
Behavioral
Treatment
Acceptance/
Resistance
Relapse
Potential
Recovery
Environment
Decision Rules
LEVEL OF CARE
1. Outpatient 2. Intensive
Outpatient
3. Medically
Monitored
Intensive
Inpatient
4. Medically
Managed
Intensive
Inpatient
ASAM Patient Placement Criteria
21 3
4 5 6
ASAM PLACEMENT CRITERIA
LEVELS OF 1. OUTPT 2. INTENSIVE 3. MED 4. MED
OF CARE OUTPT MON INPT MGD INPT
CRITERIA
Intoxication/
Withdrawal
no risk minimal some risk severe risk
Medical
Complications no risk manageable
medical
monitoring
required
24-hr acute
med. care
required
Psych/Behav
Complications no risk mild severity moderate
24-hr psych.
& addiction
Tx required
Readiness
For Change cooperative
cooperative
but requires
structure
high resist.,
needs 24-hr
motivating
Relapse
Potential
maintains
abstinence
more symptoms,
needs close
monitoring
unable to
control use in
outpt care
Recovery
Environment supportive
less support,
w/ structure
can cope
danger to
recovery,
logistical
incapacity
for outpt
• DSM-5 Substance Use Disorders: Diagnoses & Criteria
• CIWA-Ar & CINA withdrawal scores (alcohol/BZs, opioids)
• Addiction Severity Index (ASI) Composite Scores
• Imminent Risk Considerations
• Access & Support Needs/Capabilities
• ASAM Level of Care recommendations
– All adult admission levels and sub-levels
– Including Withdrawal Management
– Including Biomedically Enhanced Sub-level
– Including Co-occurring Disorder Sub-levels
(Capable, Enhanced)
• Also: If actual placement disagrees with Software,
the clinician gets to justify the discrepancy: Generating needs analysis data
Clinical Decision Support Software
Under-Matching Worsens No Show to Treatment
0%
10%
20%
30%
40%
50%
60%
70%
All Patients (N=700) Cocaine (N=183) Heroin (N=279)
From Inpatient Detox to Either Residential Rehab or Day Treatment:
All patients, High Frequency Cocaine Users and Heroin Users
Mis-matched Matched
p≤.001
p≤.001
p≤.019
Under-matched
patients’
no-show rate:
~25% worse
Under-matched
patients’
no-show rate:
~100% worse
Under-matched
patients’
no-show rate:
~300% worse
PercentNo-ShowstoNextTreatment
3-mo Drop-Out, Improvement & Stepdown Need
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Under- Matched Over-
0
1
2
3
4
5
6
7
Under- Matched Over-
% of Patients Ready for
Stepdown at F/U (vs. BL)
# ASI Subscales
Improved at F/U% Drop Out at 3-Mo F/U
0%
10%
20%
30%
40%
50%
60%
70%
Under- Matched Over-
Stepdown
Same LOC
Higher LOC
Naturalistic Match Status – According to ASAM Software
0
5
10
15
20
25
30
35
Adequate (II) Matched (III) Lesser LOC (IV)
~24-mos Before
~13 mos After
Bed-day Use Pre- vs. Post-Naturalistic L-III Placements
AnnualizedBed-Days
*


Bed-Day Utilization over 1-Yr in the VA
Bedford MA VA, N = 97
Conclusions
• ASAM Criteria: Parity-ready, published, medical necessity criteria
• The decision rules show face validity
• CONTINUUM™ technology provides good reliability & feasibility
• Good concurrent validity vs. other instruments
• Good Predictive validity overall, w/heroin, cocaine & comorbidity
• Studies show validity for undermatching, AND for overmatching
• Predictive validity found:
– across cultures/systems: public/VA; MA/NYC; Belgium/Norway
– at multiple time-frames: immediate, 30-d, 90-d & 1-year
– with multiple outcomes: no-show, global improvement,
substance use, step-down readiness, rehospitalization
Stakeholders in the Health IT Revolution
Client
Counselor
Supervisor
SystemManaged
Care
Employer/
Payer
Researcher
Accreditation Body,
Government
Society
• Operates 145 sites treating 30,000 people
• Largest behavioral health provider in U.S.
• Devotes significant resources to payer approval
• Each center has 3-5 FTEs dedicated to UR
• ~20% of cases are contested by payers
• ~30% of MD time is lost interacting w/payers
• If this administrative time is reduced only slightly,
the ASAM Software could yield substantial savings.
Case Study: CRC Health (now Acadia)
HARVARD | BUSINESS | SCHOOL
ASAM’s CONTINUUM™:
(compared to usual assessment/placement)
• 25% - 300% reductions in no shows to next stage of treatment
• 30% reduction in dropout from treatment
• 3X improvement in addiction severity outcomes at 3 months
• 25% increase in numbers of patients ready for stepdown
Leading to…
• Increased patient flow & revenues
• Staffing efficiencies (fewer incomplete intakes & UR delays)
• Improved morale & bottom line
Addiction assessment:
A new, state-of-the-art standard
Survey of Addiction Providers with an EHR
83%
14%
3%
Have you asked your EHR technology vendor(s)
if they can provide CONTINUUM™ to you?
No, but I would like them
to have this capability
Yes
No, I am not interested
OPTIONS for States/Counties implementing the 1115 Waiver:
1. Managed care organization vendor contract – at a cost of millions
2. OR, ASAM’s CONTINUUM™ - at a fraction of the cost
July 27, 2015 SMD # 15-003
Re: New Service Delivery Opportunities
for Individuals with a Substance Use Disorder
Dear State Medicaid Director:
…States should use the ASAM Criteria as they develop a residential or inpatient SUD
service continuum…
In order to receive approval…the assessment for all SUD services, level of care
and length of stay recommendations must be performed by an independent third party
that has the necessary competencies to use ASAM Patient Placement Criteria.
Specifically, an entity other than the rendering provider will use the ASAM Criteria...
DEPARTMENT OF HEALTH & HUMAN
SERVICES Centers for Medicare & Medicaid
Services 7500 Security Boulevard, Mail Stop S2-
26-12 Baltimore, Maryland 21244-1850
A National Addictions Patient Registry
Client
Counselor
Supervisor
SystemManaged
Care
Employer/
Payer
Researcher
Accreditation Body,
Government
ASAM’s
National
Coalition
Treatment
Program
Protected
Raw Data
(Identifiers +
Health Info)
Copied Data
(Stripped of Identifiers
but with
Unique Case #)
EHR
Addiction assessment:
A new, state-of-the-art standard
THE PAST…
• Non-standard, intuitive
• Telephone tag
• Proprietary criteria
• Emphasis: cost, not quality
• 1991: ASAM…teaching tool
• State-by-state Criteria
• Managed Care Study:
~50% of denials reversed
• By 2000s, SAMHSA wants
a standard
NOW…
• Standardized, quantitative
• Rapid Prior Authorization
• Published criteria
• Emphasis on cost AND quality
• 2015: ASAM…a decision tool
• A national standard for Criteria
• Managed care: Willing to pilot
AUTOMATIC prior authorization
• 2015, SAMHSA
has a standard
Addiction assessment: A Sea Change
• Enough legislation already: Begin the quality change process!
• Consumers/Providers: Push for parity in managed care UR
e.g., via the Kennedy Forum/TRI Online Appeals Guide
• Payers/States/Accreditors: Measure program services,
e.g., TRI’s ASAM Level of Care Certification Program
• Payers/MCOs: Standardize medical necessity criteria/reform UR
– drop phone prior authorization
– manage by data: via ASAM’s CONTINUUM™ data registry
For more information:
gastfriend@gmail.com
www.ASAMcontinuum.org
Advances in Treating
Chronic Pain and Addiction
Presenters:
• Michael Gavin, MBA, President, PRIUM
• Jennifer Saddy, Director of Workers’ Compensation,
American Airlines
• David R. Gastfriend, MD, Scientific Advisor, Treatment
Research Institute
Third-Party Payer Track
Moderator: Michael C. Barnes, JD, Executive Director,
Center for Lawful Access and Abuse Deterrence, and
Member, Rx and Heroin Summit National Advisory Board

More Related Content

What's hot

Rx16 advocacy wed_200_1_mendell_2manlove
Rx16 advocacy wed_200_1_mendell_2manloveRx16 advocacy wed_200_1_mendell_2manlove
Rx16 advocacy wed_200_1_mendell_2manlove
OPUNITE
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
OPUNITE
 
Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynote
OPUNITE
 
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebranRevised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
OPUNITE
 
Rx16 adv wed_1230_1_thau_2gorman
Rx16 adv wed_1230_1_thau_2gormanRx16 adv wed_1230_1_thau_2gorman
Rx16 adv wed_1230_1_thau_2gorman
OPUNITE
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
OPUNITE
 
Rx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4traven
Rx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4travenRx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4traven
Rx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4traven
OPUNITE
 
Rx16 vs ama_tues_800_harris
Rx16 vs ama_tues_800_harrisRx16 vs ama_tues_800_harris
Rx16 vs ama_tues_800_harris
OPUNITE
 
Rx16 federal tues_330_1_spitznas_2baldwin_3welch
Rx16 federal tues_330_1_spitznas_2baldwin_3welchRx16 federal tues_330_1_spitznas_2baldwin_3welch
Rx16 federal tues_330_1_spitznas_2baldwin_3welch
OPUNITE
 
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeonRx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
OPUNITE
 
Rx16 len tues_200_1_beshear_2ohr-menendez
Rx16 len tues_200_1_beshear_2ohr-menendezRx16 len tues_200_1_beshear_2ohr-menendez
Rx16 len tues_200_1_beshear_2ohr-menendez
OPUNITE
 
Rx16 adv tues_200_1_wright_2orr_3landen_4hartstebbins
Rx16 adv tues_200_1_wright_2orr_3landen_4hartstebbinsRx16 adv tues_200_1_wright_2orr_3landen_4hartstebbins
Rx16 adv tues_200_1_wright_2orr_3landen_4hartstebbins
OPUNITE
 
Rx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenRx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsen
OPUNITE
 
Rx16 advocacy tues_330_1_olsen_2raymond_3conover
Rx16 advocacy tues_330_1_olsen_2raymond_3conoverRx16 advocacy tues_330_1_olsen_2raymond_3conover
Rx16 advocacy tues_330_1_olsen_2raymond_3conover
OPUNITE
 
Rx16 federal tues_200_1_gladden_2halpin_3green
Rx16 federal tues_200_1_gladden_2halpin_3greenRx16 federal tues_200_1_gladden_2halpin_3green
Rx16 federal tues_200_1_gladden_2halpin_3green
OPUNITE
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_group
OPUNITE
 
View only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdeva
View only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdevaView only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdeva
View only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdeva
OPUNITE
 
Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynote
OPUNITE
 
Rx16 clinical wed_1230_1_shanehsaz_2waller
Rx16 clinical wed_1230_1_shanehsaz_2wallerRx16 clinical wed_1230_1_shanehsaz_2waller
Rx16 clinical wed_1230_1_shanehsaz_2waller
OPUNITE
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
OPUNITE
 

What's hot (20)

Rx16 advocacy wed_200_1_mendell_2manlove
Rx16 advocacy wed_200_1_mendell_2manloveRx16 advocacy wed_200_1_mendell_2manlove
Rx16 advocacy wed_200_1_mendell_2manlove
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
 
Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynote
 
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebranRevised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
 
Rx16 adv wed_1230_1_thau_2gorman
Rx16 adv wed_1230_1_thau_2gormanRx16 adv wed_1230_1_thau_2gorman
Rx16 adv wed_1230_1_thau_2gorman
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
 
Rx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4traven
Rx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4travenRx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4traven
Rx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4traven
 
Rx16 vs ama_tues_800_harris
Rx16 vs ama_tues_800_harrisRx16 vs ama_tues_800_harris
Rx16 vs ama_tues_800_harris
 
Rx16 federal tues_330_1_spitznas_2baldwin_3welch
Rx16 federal tues_330_1_spitznas_2baldwin_3welchRx16 federal tues_330_1_spitznas_2baldwin_3welch
Rx16 federal tues_330_1_spitznas_2baldwin_3welch
 
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeonRx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
 
Rx16 len tues_200_1_beshear_2ohr-menendez
Rx16 len tues_200_1_beshear_2ohr-menendezRx16 len tues_200_1_beshear_2ohr-menendez
Rx16 len tues_200_1_beshear_2ohr-menendez
 
Rx16 adv tues_200_1_wright_2orr_3landen_4hartstebbins
Rx16 adv tues_200_1_wright_2orr_3landen_4hartstebbinsRx16 adv tues_200_1_wright_2orr_3landen_4hartstebbins
Rx16 adv tues_200_1_wright_2orr_3landen_4hartstebbins
 
Rx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenRx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsen
 
Rx16 advocacy tues_330_1_olsen_2raymond_3conover
Rx16 advocacy tues_330_1_olsen_2raymond_3conoverRx16 advocacy tues_330_1_olsen_2raymond_3conover
Rx16 advocacy tues_330_1_olsen_2raymond_3conover
 
Rx16 federal tues_200_1_gladden_2halpin_3green
Rx16 federal tues_200_1_gladden_2halpin_3greenRx16 federal tues_200_1_gladden_2halpin_3green
Rx16 federal tues_200_1_gladden_2halpin_3green
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_group
 
View only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdeva
View only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdevaView only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdeva
View only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdeva
 
Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynote
 
Rx16 clinical wed_1230_1_shanehsaz_2waller
Rx16 clinical wed_1230_1_shanehsaz_2wallerRx16 clinical wed_1230_1_shanehsaz_2waller
Rx16 clinical wed_1230_1_shanehsaz_2waller
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
 

Viewers also liked

Lynn Webster
Lynn  WebsterLynn  Webster
Lynn Webster
OPUNITE
 
Freedom From Suffering Patient Education
Freedom From Suffering Patient EducationFreedom From Suffering Patient Education
Freedom From Suffering Patient EducationStepehn Grinstead
 
Dr. Rick Sponaugle: Chronic Pain And Addiction
Dr. Rick Sponaugle: Chronic Pain And AddictionDr. Rick Sponaugle: Chronic Pain And Addiction
Dr. Rick Sponaugle: Chronic Pain And Addiction
Robert Lee
 
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldbergerRx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
OPUNITE
 
Rx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleRx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earle
OPUNITE
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_miller
OPUNITE
 
Rx16 federal visionsession_200
Rx16 federal visionsession_200Rx16 federal visionsession_200
Rx16 federal visionsession_200
OPUNITE
 
Rx16 tpp wed_111_panel_paduda_pew
Rx16 tpp wed_111_panel_paduda_pewRx16 tpp wed_111_panel_paduda_pew
Rx16 tpp wed_111_panel_paduda_pew
OPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
OPUNITE
 
Web only rx16 treat-wed_1115_1_hudson_2bada
Web only rx16 treat-wed_1115_1_hudson_2badaWeb only rx16 treat-wed_1115_1_hudson_2bada
Web only rx16 treat-wed_1115_1_hudson_2bada
OPUNITE
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
OPUNITE
 
Rx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyRx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copy
OPUNITE
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblatt
OPUNITE
 
Web only rx16 len wed_200_1_augustine_2napier_3darr - copy
Web only rx16 len wed_200_1_augustine_2napier_3darr - copyWeb only rx16 len wed_200_1_augustine_2napier_3darr - copy
Web only rx16 len wed_200_1_augustine_2napier_3darr - copy
OPUNITE
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
OPUNITE
 
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldRx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
OPUNITE
 
Web only rx16 len wed_1230_1_daugherty_2baier-haas
Web only rx16 len wed_1230_1_daugherty_2baier-haasWeb only rx16 len wed_1230_1_daugherty_2baier-haas
Web only rx16 len wed_1230_1_daugherty_2baier-haas
OPUNITE
 

Viewers also liked (17)

Lynn Webster
Lynn  WebsterLynn  Webster
Lynn Webster
 
Freedom From Suffering Patient Education
Freedom From Suffering Patient EducationFreedom From Suffering Patient Education
Freedom From Suffering Patient Education
 
Dr. Rick Sponaugle: Chronic Pain And Addiction
Dr. Rick Sponaugle: Chronic Pain And AddictionDr. Rick Sponaugle: Chronic Pain And Addiction
Dr. Rick Sponaugle: Chronic Pain And Addiction
 
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldbergerRx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
 
Rx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleRx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earle
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_miller
 
Rx16 federal visionsession_200
Rx16 federal visionsession_200Rx16 federal visionsession_200
Rx16 federal visionsession_200
 
Rx16 tpp wed_111_panel_paduda_pew
Rx16 tpp wed_111_panel_paduda_pewRx16 tpp wed_111_panel_paduda_pew
Rx16 tpp wed_111_panel_paduda_pew
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Web only rx16 treat-wed_1115_1_hudson_2bada
Web only rx16 treat-wed_1115_1_hudson_2badaWeb only rx16 treat-wed_1115_1_hudson_2bada
Web only rx16 treat-wed_1115_1_hudson_2bada
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
 
Rx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyRx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copy
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblatt
 
Web only rx16 len wed_200_1_augustine_2napier_3darr - copy
Web only rx16 len wed_200_1_augustine_2napier_3darr - copyWeb only rx16 len wed_200_1_augustine_2napier_3darr - copy
Web only rx16 len wed_200_1_augustine_2napier_3darr - copy
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
 
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldRx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
 
Web only rx16 len wed_1230_1_daugherty_2baier-haas
Web only rx16 len wed_1230_1_daugherty_2baier-haasWeb only rx16 len wed_1230_1_daugherty_2baier-haas
Web only rx16 len wed_1230_1_daugherty_2baier-haas
 

Similar to Rx16 tpp tues_330_1_gavin_2saddy_3gastfriend

Screening, Brief Intervention and Referral to Treatment (SBIRT)
Screening, Brief Intervention and Referral to Treatment (SBIRT)Screening, Brief Intervention and Referral to Treatment (SBIRT)
Screening, Brief Intervention and Referral to Treatment (SBIRT)
California School-Based Health Alliance
 
Integration of Behavioral and Primary Care
Integration of Behavioral and Primary CareIntegration of Behavioral and Primary Care
Integration of Behavioral and Primary Care
Matthew Dunning
 
Rebecca Ruggear Senior Thesis 2013
Rebecca Ruggear Senior Thesis 2013Rebecca Ruggear Senior Thesis 2013
Rebecca Ruggear Senior Thesis 2013Rebecca Ruggear
 
Lilly Bloomington Illinois Dec 2009
Lilly Bloomington Illinois Dec 2009Lilly Bloomington Illinois Dec 2009
Lilly Bloomington Illinois Dec 2009Gilbert Gonzales
 
Why doctors prescribe opioids to known opioid abusers
Why doctors prescribe opioids to known opioid abusersWhy doctors prescribe opioids to known opioid abusers
Why doctors prescribe opioids to known opioid abusers
Paul Coelho, MD
 
Rollins et al. 2016
Rollins et al. 2016Rollins et al. 2016
Rollins et al. 2016Kyle Benbow
 
The Clinical Implications for MICA Clients and their Co-Occurring Disorders
The Clinical Implications for MICA Clients and their Co-Occurring DisordersThe Clinical Implications for MICA Clients and their Co-Occurring Disorders
The Clinical Implications for MICA Clients and their Co-Occurring Disorders
Kristen Gruenfelder
 
Rx15 tt tues_200_1_thau_2gorman
Rx15 tt tues_200_1_thau_2gormanRx15 tt tues_200_1_thau_2gorman
Rx15 tt tues_200_1_thau_2gorman
OPUNITE
 
Power Point Psy 492
Power Point Psy 492Power Point Psy 492
Power Point Psy 492jamescox1
 
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahanaRx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
OPUNITE
 
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahanaRx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
OPUNITE
 
2015 MMS Annual Report
2015 MMS Annual Report2015 MMS Annual Report
2015 MMS Annual ReportErica Noonan
 
02 keynote address_efraintalamantes
02 keynote address_efraintalamantes02 keynote address_efraintalamantes
02 keynote address_efraintalamantes
Sea Mar Community Health Centers
 
Team Lift: Predicting Medication Adherence
Team Lift: Predicting Medication AdherenceTeam Lift: Predicting Medication Adherence
Team Lift: Predicting Medication Adherence
Neil Ryan
 
The PPACA of 2010PPACA of 2010 brought many changes to the types o.docx
The PPACA of 2010PPACA of 2010 brought many changes to the types o.docxThe PPACA of 2010PPACA of 2010 brought many changes to the types o.docx
The PPACA of 2010PPACA of 2010 brought many changes to the types o.docx
suzannewarch
 
Principles of Drug Addiction Treatment
Principles of Drug Addiction TreatmentPrinciples of Drug Addiction Treatment
Principles of Drug Addiction TreatmentPk Doctors
 
The Role Of The Trauma Social Worker
The Role Of The Trauma Social WorkerThe Role Of The Trauma Social Worker
The Role Of The Trauma Social Worker
jenmsw
 

Similar to Rx16 tpp tues_330_1_gavin_2saddy_3gastfriend (20)

Thesisss.docx
Thesisss.docxThesisss.docx
Thesisss.docx
 
Screening, Brief Intervention and Referral to Treatment (SBIRT)
Screening, Brief Intervention and Referral to Treatment (SBIRT)Screening, Brief Intervention and Referral to Treatment (SBIRT)
Screening, Brief Intervention and Referral to Treatment (SBIRT)
 
Integration of Behavioral and Primary Care
Integration of Behavioral and Primary CareIntegration of Behavioral and Primary Care
Integration of Behavioral and Primary Care
 
Rebecca Ruggear Senior Thesis 2013
Rebecca Ruggear Senior Thesis 2013Rebecca Ruggear Senior Thesis 2013
Rebecca Ruggear Senior Thesis 2013
 
Lilly Bloomington Illinois Dec 2009
Lilly Bloomington Illinois Dec 2009Lilly Bloomington Illinois Dec 2009
Lilly Bloomington Illinois Dec 2009
 
Why doctors prescribe opioids to known opioid abusers
Why doctors prescribe opioids to known opioid abusersWhy doctors prescribe opioids to known opioid abusers
Why doctors prescribe opioids to known opioid abusers
 
Rollins et al. 2016
Rollins et al. 2016Rollins et al. 2016
Rollins et al. 2016
 
The Clinical Implications for MICA Clients and their Co-Occurring Disorders
The Clinical Implications for MICA Clients and their Co-Occurring DisordersThe Clinical Implications for MICA Clients and their Co-Occurring Disorders
The Clinical Implications for MICA Clients and their Co-Occurring Disorders
 
Rx15 tt tues_200_1_thau_2gorman
Rx15 tt tues_200_1_thau_2gormanRx15 tt tues_200_1_thau_2gorman
Rx15 tt tues_200_1_thau_2gorman
 
Power Point Psy 492
Power Point Psy 492Power Point Psy 492
Power Point Psy 492
 
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahanaRx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
 
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahanaRx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
 
2015 MMS Annual Report
2015 MMS Annual Report2015 MMS Annual Report
2015 MMS Annual Report
 
CDC Opioid Prescribing Guidelines
CDC Opioid Prescribing GuidelinesCDC Opioid Prescribing Guidelines
CDC Opioid Prescribing Guidelines
 
02 keynote address_efraintalamantes
02 keynote address_efraintalamantes02 keynote address_efraintalamantes
02 keynote address_efraintalamantes
 
Team Lift: Predicting Medication Adherence
Team Lift: Predicting Medication AdherenceTeam Lift: Predicting Medication Adherence
Team Lift: Predicting Medication Adherence
 
teamLift-ppt-v2
teamLift-ppt-v2teamLift-ppt-v2
teamLift-ppt-v2
 
The PPACA of 2010PPACA of 2010 brought many changes to the types o.docx
The PPACA of 2010PPACA of 2010 brought many changes to the types o.docxThe PPACA of 2010PPACA of 2010 brought many changes to the types o.docx
The PPACA of 2010PPACA of 2010 brought many changes to the types o.docx
 
Principles of Drug Addiction Treatment
Principles of Drug Addiction TreatmentPrinciples of Drug Addiction Treatment
Principles of Drug Addiction Treatment
 
The Role Of The Trauma Social Worker
The Role Of The Trauma Social WorkerThe Role Of The Trauma Social Worker
The Role Of The Trauma Social Worker
 

More from OPUNITE

Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynote
OPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
OPUNITE
 
Rx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceRx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2price
OPUNITE
 
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachioWeb only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
OPUNITE
 
Rx16 heroin wed_200_1_parker-daley_2guarino-luongo_3taylor
Rx16 heroin wed_200_1_parker-daley_2guarino-luongo_3taylorRx16 heroin wed_200_1_parker-daley_2guarino-luongo_3taylor
Rx16 heroin wed_200_1_parker-daley_2guarino-luongo_3taylor
OPUNITE
 
Rx16 clinical wed_200_1_hall_2green
Rx16 clinical wed_200_1_hall_2greenRx16 clinical wed_200_1_hall_2green
Rx16 clinical wed_200_1_hall_2green
OPUNITE
 
Rx16 federal wed_1230_1_kelly_2bohn-killorin
Rx16 federal wed_1230_1_kelly_2bohn-killorinRx16 federal wed_1230_1_kelly_2bohn-killorin
Rx16 federal wed_1230_1_kelly_2bohn-killorin
OPUNITE
 

More from OPUNITE (7)

Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynote
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Rx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceRx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2price
 
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachioWeb only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
 
Rx16 heroin wed_200_1_parker-daley_2guarino-luongo_3taylor
Rx16 heroin wed_200_1_parker-daley_2guarino-luongo_3taylorRx16 heroin wed_200_1_parker-daley_2guarino-luongo_3taylor
Rx16 heroin wed_200_1_parker-daley_2guarino-luongo_3taylor
 
Rx16 clinical wed_200_1_hall_2green
Rx16 clinical wed_200_1_hall_2greenRx16 clinical wed_200_1_hall_2green
Rx16 clinical wed_200_1_hall_2green
 
Rx16 federal wed_1230_1_kelly_2bohn-killorin
Rx16 federal wed_1230_1_kelly_2bohn-killorinRx16 federal wed_1230_1_kelly_2bohn-killorin
Rx16 federal wed_1230_1_kelly_2bohn-killorin
 

Recently uploaded

Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
FFragrant
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
sisternakatoto
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
Sujoy Dasgupta
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
i3 Health
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Dr KHALID B.M
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 

Recently uploaded (20)

Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 

Rx16 tpp tues_330_1_gavin_2saddy_3gastfriend

  • 1. Advances in Treating Chronic Pain and Addiction Presenters: • Michael Gavin, MBA, President, PRIUM • Jennifer Saddy, Director of Workers’ Compensation, American Airlines • David R. Gastfriend, MD, Scientific Advisor, Treatment Research Institute Third-Party Payer Track Moderator: Michael C. Barnes, JD, Executive Director, Center for Lawful Access and Abuse Deterrence, and Member, Rx and Heroin Summit National Advisory Board
  • 2. Disclosures • Michael Gavin, MBA; Jennifer Saddy; and Michael C. Barnes, JD, have disclosed no relevant, real, or apparent personal or professional financial relationships with proprietary entities that produce healthcare goods and services. • David R. Gastfriend, MD – Future royalty: American Society of Addiction Medicine
  • 3. Disclosures • All planners/managers hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. • The following planners/managers have the following to disclose: – John J. Dreyzehner, MD, MPH, FACOEM – Ownership interest: Starfish Health (spouse) – Robert DuPont – Employment: Bensinger, DuPont & Associates-Prescription Drug Research Center
  • 4. Learning Objectives 1. Outline mental and behavioral issues and their influence on chronic pain. 2. Identify strategies to address psychosocial pain issues when managing chronic pain and claims involving chronic pain. 3. Explain the basis and impacts of the new federal requirements for state Medicaid directors to implement the ASAM Criteria. 4. Describe a tool for implementing the new ASAM Criteria requirement.
  • 5. THIRD-PARTY PAYER TRACK: ADVANCES IN TREATING CHRONIC PAIN AND ADDICTION Michael Gavin, PRIUM 5
  • 6. Disclosure Statement Michael Gavin, President of PRIUM, wishes to disclose that PRIUM is a wholly owned subsidiary of Ameritox. Michael will present this content in a fair and balanced manner.
  • 7. Learning Objectives 1. Outline mental and behavioral issues and their influence on chronic pain. 2. Identify strategies to address psychosocial pain issues when managing chronic pain and claims involving chronic pain. 3. Explain the basis and impacts of the new federal requirements for state Medicaid directors to implement the ASAM Criteria. 4. Describe a tool for implementing the new ASAM Criteria requirement.
  • 8. Comorbid AMI, SUD, CNCP “ 9 million persons in the United States report long-term medical use of opioids.” - CDC MMWR 2012 Each of the individual populations drives significant healthcare costs; the intersections of the populations represent particularly complex patients that require innovative and focused management
  • 9. A. Disease impacts mental health • 30% of those living with a non-communicable disease report a concurrent mental disorder.1 B. Mental Health impacts physical health • Conversely, more than two-thirds of people with a mental disorder have been shown to have at least one other chronic NCD. 1 C. Psychosocial and Socioeconomic status modify both effects • An individual of lesser social and economic status is more likely to suffer comorbid mental illness with a non-communicable disease or disorder. 2 1. (Druss BG, Mental disorders and medical comorbidity.) 2. (Marnett K, Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study.) 9 Bidirectional Association Physical health and mental health are intrinsically linked. Psychological factors are reciprocally interactive in the initiation and expression of the pathology of chronic disease.
  • 10. • Adverse Childhood Exposures • The most prevalent of the 7 measured exposures was substance abuse in the household at (~26%) • Likelihood of childhood exposure: • 25% chance to have been exposed to 1 category • 6% chance to have been exposed to 4 or more categories • Likelihood of illicit drug use: • 11% with 1 exposure • 28% with 4 or more exposures 10 Predicting Substance Abuse The ACE study followed Kaiser patients from 1995-97. While chronic disease and risky health behaviors are strongly predicted by ACEs, interventions focused on children are far from implementation.
  • 11. A. Duration1 • 1-year disability risk is doubled by each of: – Receiving more than 7 day supply of opioids within the first 6 weeks post injury. – Receipt of 2 opioid prescriptions in 6 weeks post injury. – Receipt of >150mg MED in 6 weeks post injury. B. Mortality2,3 • Nationally, persons with anxiety/depression have a 60% higher mortality and die an average of 8 years earlier than persons without these illnesses. • Anxiety/depression attribute to 88,000 deaths each year. • Prescription painkillers killed more than 16,000 in 2013 or 44 people/day. C. Expenditures4,5 • Employees treated for depression (most commonly occurring) incurred annual per capita health and disability costs of $5,415. • Compared with claims not prescribed opioids, claims prescribed SA opioids are 2.8 times more expensive and claims prescribed LA opioids are 9.3 times more expensive. 1. GM Franklin et al., “early opioid prescription and subsequent disability among workers with back injuries: the Disability Risk Identification Study Cohort.” Spine 33.2 (2008) 2. Pratt, Laura A., et al., “Excess mortality due to depression and anxiety in the United States.” General Hospital Psychiatry (2015) 3. CDC. National Vital Statistics System mortality data. (2015) 4. Druss, BG et al., “Health and disability costs of depressive illness in a major US corporation.” Am. Journal of Psychiatry 157.8 (2000) 5. White, JA., et al., “Thhe effect of opioid use on workers’ compensation claim cost in the state of Michigan. “J. of Occ and Env. Med (2012) 11 Impact on Claims Comorbid AMI and CNCP are synergistically disabling and treated as a single disease state using opiates. Co-occurring AMI and CNCP cause greater disability than each condition taken separately.
  • 12. Primary Care Problem? Family practice and internal medicine doctors are responsible for about 28 million opioid claims vs. a little over 3 million for pain management and interventional pain management combined.
  • 13. • Stigma contributes to a host of adverse outcomes for people with SUD: – Poor mental and physical health.1,2 – Non-completion of treatment for SUD.3 – Delayed recovery and reintegration.4,5 • Stigma also presents a barrier to treatment: – Causing lowered utilization,6,7 – And differential treatment.8 Influence of Stigma 1. Stigma, discrimination and the health of illicit drug users. Ahern J., Stuber J., Galea S. Article Drug Alcohol Depend, 2007 2. On stigma and its consequences: evidence from a longitudinal study of men with dual diagnoses of mental illness and substance abuse Link B., Struening E. L., Rahav M., Phelan J. C., Nuttbrock L. Article J Health Soc Behav, 1997 3. Perceptions of discriminatory treatment by staff as predictorsof drug treatment completion: utility of a mixed methods approach Brener L., von Hippel W., von Hippel C., Resnick I., Treloar C. Article Drug Alcohol Rev, 2010 4. The contextual factors that foster and hinder the process of recoveryfor alcohol dependentwomen Brewer M. K. Article J Addict Nurs, 2006 5. Nowhere to go: how stigma limits the options of female drug users after release from jail van Olphen J., Eliason M. J., Freudenberg N., Barnes M. Article Subst Abuse Treat Prev Policy, 2009 6. Utilization of drug treatment programs by methamphetamine users: the role of social stigma Semple S. J., Grant I., Patterson T. L. Article Am J Addict, 2005 7. Equity of access to treatment, and barriers to treatment for illicit drug use in Australia Digiusto E., Treloar C. Article Addiction, 2007 8. Are drug treatment services only for ‘thieving junkie scumbags’? Drug users and the management of stigmatised identities Radcliffe P., Stevens A. Article Soc Sci Med, 2008
  • 14. Havassy BE, Alvidrez J, Mericle AA. Disparities in Use of Mental Health and Substance Abuse Services by Persons with Co-occurring Disorders.Psychiatric services (Washington, DC). 2009;60(2):217-223. doi:10.1176/appi.ps.60.2.217. 14 Comorbid Treatment Rates Patients with co-occurring disorders need to navigate two systems of care to obtain treatment. Those who receive treatment in one sector may not receive adequate treatment in the other sector.
  • 15. Political Hope? “…we need a revolution in this country in terms of mental health treatment.“ - Sen. Bernie Sanders Democratic Presidential Debate, 1/17/16 "We have to move away from treating the use of drugs as a crime and instead, move it to where it belongs, as a health issue.” - Sec. Hillary Clinton Democratic Presidential Debate, 1/17/16 "You have the most conservative Republican governors and the most liberal Democratic governors agreeing" on the urgent need to get something done. - Gov. Pete Shumliin, VT, NY Times, 2/22/16 “The victims of addiction deserve treatment...“ - Gov. Chris Christie ABC News, 1/12/16 “It’s very debilitating when you have a loved one who’s struggling and you can’t control it. I don’t know what it’s like to lose a daughter. But I almost did.” Gov. Jeb Bush Huffington Post, 11/5/15 “This is a problem that, for me, I understand firsthand.” - Sen. Ted Cruz Republican Presidential Debate, 2/6/16
  • 16. • Web: www.prium.com • Blog: www.priumevidencebased.com • Twitter: @PRIUM1 • LinkedIn: https://www.linkedin.com/company/prium- medical-cost-management 16 Connect with PRIUM
  • 17. THIRD-PARTY PAYER TRACK: ADVANCES IN TREATING CHRONIC PAIN AND ADDICTION Jennifer Saddy, American Airlines 17
  • 18. Learning Objectives 1. Outline mental and behavioral issues and their influence on chronic pain. 2. Identify strategies to address psychosocial pain issues when managing chronic pain and claims involving chronic pain. 3. Explain the basis and impacts of the new federal requirements for state Medicaid directors to implement the ASAM Criteria. 4. Describe a tool for implementing the new ASAM Criteria requirement.
  • 19. • Redesign of the American Airlines Workers’ Compensation (WC) program in 2014 after merger with US Airways – Redefined the roles of the WC team – Program covers over 120,000 employees and 3 wholly owned subsidiaries. – At least 15 union groups. • New program focused on 2 claim tracks: – New workers’ compensation claims, – And the legacy on-going existing claims. American Airlines WC
  • 20. • Early intervention of the claim process and additional resources provided for the employee – Provide more meaningful interaction with the injured employees – Employer, Adjuster and Nurse Case Manager • Direction of care & partner with the treating physician (to the extent that is allowable per state law). • Collaboration and open communication between all parties in the claims process New WC Claims
  • 21. • Early intervention is key to meaningful impact for the injured employee – Need to identify early red flags such as unclear diagnosis and increasing opioid usage • Provide the additional resources early in the process to ensure appropriate treatment plan – Treating physician – Physician to physician discussions – Nurse Case Manager – Utilization Review Chronic Pain Claims
  • 22. • 5,874 WC claims open December 2013 some over 20 years old • Goal was to resolve these claims but chronic pain and pharmacy usage was a significant challenge • Significant pharmacy usage in claims 2+ years old and growing pharmacy trend and ongoing disability • Engaged pharmacy experts and physician resources in attempts to change trajectory of medical care to allow more function of the injured employee Existing WC Claims
  • 23. • 40% reduction in open Workers Compensation claims for American Airlines since December 2013 • Reduction in pharmacy costs by 5% (even with 30% more claims with the US Airways merger) • Reduced disability by an average of 11 days or 25% Results
  • 24. Precise Data for Imprecise Behavior: Why National Standards Make a Difference David R. Gastfriend MD Chief Architect, CONTINUUMTM – The ASAM Criteria Decision Engine Scientific Advisor – Treatment Research Institute
  • 25. Disclosure of Relevant Financial Relationships Name Commercial Interests Relevant Financial Relationships: What Was Received Relevant Financial Relationships: For What Role No Relevant Financial Relationships with Any Commercial Interests David Gastfriend Recovery Search Alkermes Kaleo Indivior Royalty from ASAM, Inc. Stock,Consulting Consulting Consulting Pres. & CEO Former VP, Sci. Communications Adv. Board Adv. Board
  • 26. ACA, Parity & Health IT Acts: Huge Implications The Affordable Care Act (2010) • Phasing-out fee-for-service • Penalties now charged for preventable readmissions • By 2018, 50% of CMS funds will be paid through alternative payment methods • Value-based payment, Case-based rates, Pay-for-performance • Elevates importance of SUD because tens of millions with higher SUD prevalence become insured • SUD gets a seat at the table …but will it be THE HOT SEAT???
  • 27. ACA, Parity & Health IT Acts: Huge Implications The Mental Health Parity and Addiction Equity Act (2008): • Rules & lawsuits – slow in coming, but THEY’RE HERE • Published medical necessity criteria, e.g., ASAM Criteria • Equal coverage for SUD as for medical/surgical care • No “non-quantitative treatment limits” if not used for med/surg benefits (e.g., prior authorization) • Kennedy Forum & TRI Online Appeals Guide • SUD finally gets a seat at the table www.thekennedyforum.org www.tresearch.org
  • 28. ACA, Parity & Health IT Acts: Huge Implications The Health InfoTech (HITECH) Act (2009): Nowhere to hide • Incentives for EHR adoption in general healthcare • SUD behind the curve – competitive pressures now driving • Data integration on the way…HIPAA & 42CFR – being resolved: • SAMHSA’s Consent to Share (C2S) web-app is coming: Patient selects which data can be shared between which providers & systems • Not only data storage/retrieval, but also clinical decision support and quality/outcomes tracking …for pay-for-performance
  • 29. PREVALENCE OF CO-MORBIDITY (Medicaid; Percent with Chronic Medical +/- Behavioral Disease) 29 Hypertension Diabetes Coronary Heart Disease Congestive Heart Failure Asthma and/or COPD 31.4% 32.1% 26.3% 30.1% 23.8% 68.6% 67.9% 73.7% 69.9% 76.2% No Behavioral Health Problem With 1 or More Behavioral Health Problem 29 Boyd, C., Clark, R., Leff, B., Richards, T., Weiss, C., Wolff, J. (2011, August). Clarifying Multimorbidity for Medicaid Programs to Improve Targeting and Delivering Clinical Services. Presented to SAMHSA, Rockville, MD.
  • 30. IMPACT OF CO-MORBIDITY ON PER CAPITA COSTS (Medicaid-Only Beneficaries with Co-Occurring Disorders) 30Boyd, C., Clark, R., Leff, B., Richards, T., Weiss, C., Wolff, J. (2011, August). Clarifying Multimorbidity for Medicaid Programs to Improve Targeting and Delivering Clinical Services. Presented to SAMHSA, Rockville, MD. 30
  • 31.
  • 32. Addiction Assessment & Treatment Planning: • Non-standard, “intuitive”, then “find out the rest later…” • Managed Care wants more data: Telephone tag (90 min – 3 days) • Most insurers’ medical necessity criteria are proprietary • Absent precision & validity, emphasis is on cost, not quality • 1991: ASAM Patient Placement Criteria…a teaching tool • States create their own Criteria (CASAM, MASAM, NYSAM…) • “ASAM” in Major US MCO: ~50% of cases were denials • on appeal: ~50% reversed; on review ~50% reversed again! • By 2000s, SAMHSA & CSAT called on ASAM for a standard
  • 33. Modality Matching: Many studies, e.g., Project MATCH – but few findings (Gastfriend & McLellan, Med Clin NA, 1997) Placement Matching: Multiple studies; ASAM model – consistent signals (Gastfriend, Addiction Treatment Matching, Haworth Press, 2004) Support: • NIDA: Validation - R01-DA08781 & K24-DA00427 • NIAAA: ASAM Software - SBIR grant R44-AA12004 • CSAT: Access to Recovery Initiative - grant 270-02-7120 • Belgian National Fund for Scientific Research • Belgian American Educational Foundation • Central Norway Health Trust /Rusbehandling Midt-Norge • SAMHSA: Open Behavioral Health IT Architecture Program Advances in Treatment Matching
  • 34. ASAM Text: Hundreds of Decision Rules To place patients in the least intensive & restrictive care that meets the patient’s multi-dimensional needs and affords optimal treatment outcome www.ASAMcriteria.org www.haworthpress.com
  • 35. Screening Diagnosis Severity Readiness & Relapse Potential Patient Placement Criteria DIMENSIONS Intoxication Withdrawal Biomedical Emotional Behavioral Treatment Acceptance/ Resistance Relapse Potential Recovery Environment Decision Rules LEVEL OF CARE 1. Outpatient 2. Intensive Outpatient 3. Medically Monitored Intensive Inpatient 4. Medically Managed Intensive Inpatient ASAM Patient Placement Criteria 21 3 4 5 6
  • 36. ASAM PLACEMENT CRITERIA LEVELS OF 1. OUTPT 2. INTENSIVE 3. MED 4. MED OF CARE OUTPT MON INPT MGD INPT CRITERIA Intoxication/ Withdrawal no risk minimal some risk severe risk Medical Complications no risk manageable medical monitoring required 24-hr acute med. care required Psych/Behav Complications no risk mild severity moderate 24-hr psych. & addiction Tx required Readiness For Change cooperative cooperative but requires structure high resist., needs 24-hr motivating Relapse Potential maintains abstinence more symptoms, needs close monitoring unable to control use in outpt care Recovery Environment supportive less support, w/ structure can cope danger to recovery, logistical incapacity for outpt
  • 37. • DSM-5 Substance Use Disorders: Diagnoses & Criteria • CIWA-Ar & CINA withdrawal scores (alcohol/BZs, opioids) • Addiction Severity Index (ASI) Composite Scores • Imminent Risk Considerations • Access & Support Needs/Capabilities • ASAM Level of Care recommendations – All adult admission levels and sub-levels – Including Withdrawal Management – Including Biomedically Enhanced Sub-level – Including Co-occurring Disorder Sub-levels (Capable, Enhanced) • Also: If actual placement disagrees with Software, the clinician gets to justify the discrepancy: Generating needs analysis data Clinical Decision Support Software
  • 38. Under-Matching Worsens No Show to Treatment 0% 10% 20% 30% 40% 50% 60% 70% All Patients (N=700) Cocaine (N=183) Heroin (N=279) From Inpatient Detox to Either Residential Rehab or Day Treatment: All patients, High Frequency Cocaine Users and Heroin Users Mis-matched Matched p≤.001 p≤.001 p≤.019 Under-matched patients’ no-show rate: ~25% worse Under-matched patients’ no-show rate: ~100% worse Under-matched patients’ no-show rate: ~300% worse PercentNo-ShowstoNextTreatment
  • 39. 3-mo Drop-Out, Improvement & Stepdown Need 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Under- Matched Over- 0 1 2 3 4 5 6 7 Under- Matched Over- % of Patients Ready for Stepdown at F/U (vs. BL) # ASI Subscales Improved at F/U% Drop Out at 3-Mo F/U 0% 10% 20% 30% 40% 50% 60% 70% Under- Matched Over- Stepdown Same LOC Higher LOC Naturalistic Match Status – According to ASAM Software
  • 40. 0 5 10 15 20 25 30 35 Adequate (II) Matched (III) Lesser LOC (IV) ~24-mos Before ~13 mos After Bed-day Use Pre- vs. Post-Naturalistic L-III Placements AnnualizedBed-Days *   Bed-Day Utilization over 1-Yr in the VA Bedford MA VA, N = 97
  • 41. Conclusions • ASAM Criteria: Parity-ready, published, medical necessity criteria • The decision rules show face validity • CONTINUUM™ technology provides good reliability & feasibility • Good concurrent validity vs. other instruments • Good Predictive validity overall, w/heroin, cocaine & comorbidity • Studies show validity for undermatching, AND for overmatching • Predictive validity found: – across cultures/systems: public/VA; MA/NYC; Belgium/Norway – at multiple time-frames: immediate, 30-d, 90-d & 1-year – with multiple outcomes: no-show, global improvement, substance use, step-down readiness, rehospitalization
  • 42. Stakeholders in the Health IT Revolution Client Counselor Supervisor SystemManaged Care Employer/ Payer Researcher Accreditation Body, Government Society
  • 43. • Operates 145 sites treating 30,000 people • Largest behavioral health provider in U.S. • Devotes significant resources to payer approval • Each center has 3-5 FTEs dedicated to UR • ~20% of cases are contested by payers • ~30% of MD time is lost interacting w/payers • If this administrative time is reduced only slightly, the ASAM Software could yield substantial savings. Case Study: CRC Health (now Acadia) HARVARD | BUSINESS | SCHOOL
  • 44.
  • 45.
  • 46.
  • 47.
  • 48.
  • 49. ASAM’s CONTINUUM™: (compared to usual assessment/placement) • 25% - 300% reductions in no shows to next stage of treatment • 30% reduction in dropout from treatment • 3X improvement in addiction severity outcomes at 3 months • 25% increase in numbers of patients ready for stepdown Leading to… • Increased patient flow & revenues • Staffing efficiencies (fewer incomplete intakes & UR delays) • Improved morale & bottom line Addiction assessment: A new, state-of-the-art standard
  • 50. Survey of Addiction Providers with an EHR 83% 14% 3% Have you asked your EHR technology vendor(s) if they can provide CONTINUUM™ to you? No, but I would like them to have this capability Yes No, I am not interested
  • 51. OPTIONS for States/Counties implementing the 1115 Waiver: 1. Managed care organization vendor contract – at a cost of millions 2. OR, ASAM’s CONTINUUM™ - at a fraction of the cost July 27, 2015 SMD # 15-003 Re: New Service Delivery Opportunities for Individuals with a Substance Use Disorder Dear State Medicaid Director: …States should use the ASAM Criteria as they develop a residential or inpatient SUD service continuum… In order to receive approval…the assessment for all SUD services, level of care and length of stay recommendations must be performed by an independent third party that has the necessary competencies to use ASAM Patient Placement Criteria. Specifically, an entity other than the rendering provider will use the ASAM Criteria... DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2- 26-12 Baltimore, Maryland 21244-1850
  • 52. A National Addictions Patient Registry Client Counselor Supervisor SystemManaged Care Employer/ Payer Researcher Accreditation Body, Government ASAM’s National Coalition Treatment Program Protected Raw Data (Identifiers + Health Info) Copied Data (Stripped of Identifiers but with Unique Case #) EHR
  • 53. Addiction assessment: A new, state-of-the-art standard THE PAST… • Non-standard, intuitive • Telephone tag • Proprietary criteria • Emphasis: cost, not quality • 1991: ASAM…teaching tool • State-by-state Criteria • Managed Care Study: ~50% of denials reversed • By 2000s, SAMHSA wants a standard NOW… • Standardized, quantitative • Rapid Prior Authorization • Published criteria • Emphasis on cost AND quality • 2015: ASAM…a decision tool • A national standard for Criteria • Managed care: Willing to pilot AUTOMATIC prior authorization • 2015, SAMHSA has a standard
  • 54. Addiction assessment: A Sea Change • Enough legislation already: Begin the quality change process! • Consumers/Providers: Push for parity in managed care UR e.g., via the Kennedy Forum/TRI Online Appeals Guide • Payers/States/Accreditors: Measure program services, e.g., TRI’s ASAM Level of Care Certification Program • Payers/MCOs: Standardize medical necessity criteria/reform UR – drop phone prior authorization – manage by data: via ASAM’s CONTINUUM™ data registry
  • 55.
  • 57. Advances in Treating Chronic Pain and Addiction Presenters: • Michael Gavin, MBA, President, PRIUM • Jennifer Saddy, Director of Workers’ Compensation, American Airlines • David R. Gastfriend, MD, Scientific Advisor, Treatment Research Institute Third-Party Payer Track Moderator: Michael C. Barnes, JD, Executive Director, Center for Lawful Access and Abuse Deterrence, and Member, Rx and Heroin Summit National Advisory Board